EGHAM, England, May 10, 2021 /PRNewswire/ -- Essential Pharma, an international specialty pharma company focused on maintaining access to well-established, "at risk" products essential to patients ...
Egham, UK – 6th February 2025 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically ...
Gyrus Capital has held a final close on a €700 million single-asset continuation vehicle for Essential Pharma. Essential is a specialty pharma group focused on ensuring that patients have access to ...
EGHAM, England, Feb. 9, 2021 /PRNewswire/ -- Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, "at risk" products to patients across multiple ...
UK – 14 April 2026 – Renaissance Pharma Limited, an Essential Pharma company focused on development stage assets, today announces that the US Food and Drug Administration (FDA) has granted Fast Track ...
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA ...
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results